GSA Capital Partners LLP Sells 52,213 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

GSA Capital Partners LLP lessened its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 84.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 9,417 shares of the biotechnology company’s stock after selling 52,213 shares during the period. GSA Capital Partners LLP’s holdings in Arcturus Therapeutics were worth $219,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Millennium Management LLC grew its holdings in Arcturus Therapeutics by 250.1% in the second quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock worth $13,515,000 after purchasing an additional 396,505 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of Arcturus Therapeutics by 22.4% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock worth $38,061,000 after buying an additional 286,546 shares during the last quarter. ARK Investment Management LLC increased its position in Arcturus Therapeutics by 16.3% during the 2nd quarter. ARK Investment Management LLC now owns 1,964,964 shares of the biotechnology company’s stock valued at $47,847,000 after buying an additional 275,315 shares in the last quarter. Empire Life Investments Inc. purchased a new position in Arcturus Therapeutics during the third quarter valued at $3,498,000. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in Arcturus Therapeutics by 111.0% in the first quarter. Jacobs Levy Equity Management Inc. now owns 95,924 shares of the biotechnology company’s stock worth $3,239,000 after acquiring an additional 50,470 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, COO Pad Chivukula sold 12,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the transaction, the chief operating officer now owns 435,334 shares of the company’s stock, valued at approximately $9,037,533.84. This represents a 2.68 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 15.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Leerink Partnrs upgraded shares of Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. Leerink Partners started coverage on Arcturus Therapeutics in a research report on Monday, August 12th. They issued an “outperform” rating and a $70.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $71.40.

Arcturus Therapeutics Price Performance

Shares of Arcturus Therapeutics stock opened at $16.91 on Monday. Arcturus Therapeutics Holdings Inc. has a 1-year low of $14.93 and a 1-year high of $45.00. The company’s fifty day simple moving average is $20.22 and its 200-day simple moving average is $23.60. The stock has a market capitalization of $458.09 million, a PE ratio of -7.62 and a beta of 2.64.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The business had revenue of $41.67 million during the quarter, compared to analyst estimates of $49.16 million. During the same quarter in the previous year, the company posted ($0.61) earnings per share. As a group, research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.31 EPS for the current year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.